Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 18/20 | 0.67 |
| ▸ | TNF | P01375 | 3/20 | 0.67 |
| ▸ | IL1B | P01584 | 3/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768307 | 0.96 | CRBN (0.65) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768465 | 0.92 | CRBN (0.69) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768445 | 0.92 | CRBN (0.69) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768355 | 0.92 | CRBN (0.69) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2251019 | 0.92 | CRBN (0.79) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30138426 | 0.92 | CRBN (0.79) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768309 | 0.90 | CRBN (0.66) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768450 | 0.90 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768449 | 0.90 | CRBN (0.77) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768382 | 0.89 | CRBN (0.72) | CRBNIKZF3TNFIL1BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
| US-9587281-B2 | Cereblon isoforms and their use as biomarkers for therapeutic treatment | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | CRBN 1/4885IKZF3 1569/4885TNF 4080/4885 |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | CRBN 1/4885IKZF3 1569/4885TNF 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.